Outcome of the Board meeting held on 13th June 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indrayani Biotech Limited reported audited consolidated results for the year ended March 31, 2025, showing a sharp swing from profit to loss. Full-year revenue from operations fell about 22% to Rs 13,022.84 lakhs (from Rs 16,622.56 lakhs in FY24). The company posted a loss after tax of Rs 610.75 lakhs compared to a profit of Rs 1,042.25 lakhs last year, with EPS turning negative at Rs (1.35) versus Rs 1.40. Finance costs rose roughly 19% to Rs 1,176.27 lakhs, squeezing margins further. On the balance sheet, short-term borrowings jumped nearly 75% to Rs 7,165.72 lakhs, while cash on hand fell to just Rs 28.82 lakhs. Operating cash flow remained negative at Rs (674.18) lakhs. Statutory auditor Venkatesh & Co. issued an unmodified opinion, though financials of three subsidiaries and two step-down subsidiaries were management-certified and not audited.
Full-year results show a significant deterioration—declining revenue, negative profitability, rising debt, and weak cash generation. The surge in short-term borrowings against very low cash heightens liquidity risk. Shareholders should monitor debt servicing capacity and subsidiary-level performance closely.